The effect of treatment with vincristine on transient evoked and distortion product otoacoustic emissions

Riga, Maria; Psarommatis, Ioannis; Korres, Stavros; Lyra, Ch.; Papadeas, E.; Varvutsi, M.; Ferekidis, E.; Apostolopoulos, Nicholas

doi:10.1016/j.ijporl.2005.10.011

Cited by 11 publications

(9 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the children received multiple chemotherapy drugs, only carboplatin has well-documented ototoxic side effects. The main side effect of vincristine is neurotoxicity, and when given as a single chemotherapy agent, it is not thought to alter measurements of DPOAEs in children [23]. Primary side effects associated with topotecan and etoposide include myelosuppression, nausea, vomiting, and alopecia.…”

Section: Methodsmentioning

confidence: 99%

Monitoring carboplatin ototoxicity with distortion-product otoacoustic emissions in children with retinoblastoma

Bhagat

Bass

White

et al. 2010

International Journal of Pediatric Otorhinolaryngology

View full text Add to dashboard Cite

Objective Carboplatin is a common chemotherapy agent with potential ototoxic side effects that is used to treat a variety of pediatric cancers, including retinoblastoma. Retinoblastoma is a malignant tumor of the retina that is usually diagnosed in young children. Distortion-product otoacoustic emission tests offer an effective method of monitoring for ototoxicity in young children. This study was designed to compare measurements of distortion-product otoacoustic emissions obtained before and after several courses of carboplatin chemotherapy in order to examine if (a) mean distortion-product otoacoustic emission levels were significantly different; and (b) if criterion reductions in distortion-product otoacoustic emission levels were observed in individual children. Methods A prospective repeated measures study. Ten children with a median age of 7.6 months (range, 3–72 months) diagnosed with unilateral or bilateral retinoblastoma were examined. Distortion-product otoacoustic emissions were acquired from both ears of the children with 65/55 dB SPL primary tones (f2= 793–7996 Hz) and a frequency resolution of 3 points/octave. Distortion-product otoacoustic emission levels in dB SPL were measured before chemotherapy treatment (baseline measurement) and after 3–4 courses of chemotherapy (interim measurement). Comparisons were made between baseline and interim distortion-product otoacoustic emission levels (collapsed across ears). Evidence of ototoxicity was based on criterion reductions (≥ 6 dB) in distortion-product otoacoustic emission levels. Results Significant differences between baseline and interim mean distortion-product otoacoustic emission levels were only observed at f2=7996 Hz. Four children exhibited criterion reductions in distortion-product otoacoustic emission levels. Conclusions Mean distortion-product otoacoustic emission levels at most frequencies were not changed following 3–4 courses of carboplatin chemotherapy in children with retinoblastoma. However, on an individual basis, children receiving higher doses of carboplatin exhibited criterion reductions in distortion-product otoacoustic emission level at several frequencies. These findings suggest that higher doses of carboplatin affect outer hair cell function, and distortion-product otoacoustic emission tests can provide useful information when monitoring children at risk of developing carboplatin ototoxicity.

show abstract

Section: Methodsmentioning

confidence: 99%

Monitoring carboplatin ototoxicity with distortion-product otoacoustic emissions in children with retinoblastoma

Bhagat

Bass

White

et al. 2010

International Journal of Pediatric Otorhinolaryngology

View full text Add to dashboard Cite

show abstract

“…More over the better clinical condition of the child at the completion of early intensive phase of chemotherapy than at baseline evaluation could have also resulted in better thresholds post therapy. Riga et al 21 have reported a similar study on ten children with leukemia receiving chemotherapy as per BFM-95 protocol in which DPOAEs revealed a declining tendency, however changes did not reach statistical significance. Pure tone audiometry and stapedial reflex thresholds were not altered.…”

Section: Resultsmentioning

confidence: 93%

Does Vincristine affect Cochlear function in children with acute lymphoblastic leukaemia?

Rao

Kumar²,

Bhat

et al. 2016

Bangla J Med

View full text Add to dashboard Cite

show abstract

“…Vincristine was a part of chemotherapy in concert with carboplatin and other agents such as etoposide and teniposide. Vincristine has been reported to be ototoxic only in high doses due to neurotoxicity . None of our patients had high‐dose vincristine and there was no significant difference in vincristine dosage between the children who developed hearing loss (n = 18) and those who retained normal hearing (n = 53).…”

Section: Discussionmentioning

confidence: 99%

Clinical and genetic associations for carboplatin‐related ototoxicity in children treated for retinoblastoma: A retrospective noncomparative single‐institute experience

Soliman

D'Silva

Dimaras

et al. 2018

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

The effect of treatment with vincristine on transient evoked and distortion product otoacoustic emissions

Cited by 11 publications

References 28 publications

Monitoring carboplatin ototoxicity with distortion-product otoacoustic emissions in children with retinoblastoma

Monitoring carboplatin ototoxicity with distortion-product otoacoustic emissions in children with retinoblastoma

Does Vincristine affect Cochlear function in children with acute lymphoblastic leukaemia?

Clinical and genetic associations for carboplatin‐related ototoxicity in children treated for retinoblastoma: A retrospective noncomparative single‐institute experience

Contact Info

Product

Resources

About